NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $85.15 +1.07 (+1.27%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Lantheus Stock (NASDAQ:LNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantheus alerts:Sign Up Key Stats Today's Range$83.31▼$85.3850-Day Range$84.08▼$116.6952-Week Range$50.20▼$126.89Volume1.79 million shsAverage Volume1.00 million shsMarket Capitalization$5.92 billionP/E Ratio14.17Dividend YieldN/APrice Target$122.50Consensus RatingModerate Buy Company OverviewLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Lantheus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks95th Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 95% of companies evaluated by MarketBeat, and ranked 56th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has only been the subject of 3 research reports in the past 90 days.Read more about Lantheus' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.02% Earnings GrowthEarnings for Lantheus are expected to grow by 11.02% in the coming year, from $5.99 to $6.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 14.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 14.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.69.Price to Book Value per Share RatioLantheus has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.03% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.67 Percentage of Shares Shorted6.03% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Lantheus has recently decreased by 1.41%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment0.72 News SentimentLantheus has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Lantheus this week, compared to 7 articles on an average week.Search Interest20 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows6 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesBuy Rating Reaffirmed for Lantheus Amid Discounted Valuation and Promising Growth CatalystsNovember 13 at 12:13 AM | markets.businessinsider.comLantheus reaffirms outlook for PYLARIFY’s ‘blockbuster status’ for 2025November 11 at 8:17 PM | markets.businessinsider.comTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. November 13, 2024 | Crypto 101 Media (Ad)Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025November 11 at 7:39 AM | globenewswire.comLantheus (NASDAQ:LNTH) Upgraded at StockNews.comNovember 11 at 4:05 AM | americanbankingnews.comLantheus price target lowered to $120 from $135 at TruistNovember 9, 2024 | markets.businessinsider.comResults: Lantheus Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsNovember 9, 2024 | finance.yahoo.comLantheus Holdings: Q3 Results Were Good But Market OverreactedNovember 8, 2024 | seekingalpha.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH shares have increased by 37.3% and is now trading at $85.15. View the best growth stocks for 2024 here. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings results on Wednesday, July, 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by $0.07. Lantheus's quarterly revenue was up 22.5% on a year-over-year basis. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' top institutional shareholders include Westfield Capital Management Co. LP (2.18%), Reinhart Partners LLC. (1.79%), Charles Schwab Investment Management Inc. (1.18%) and Swedbank AB (1.04%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings7/31/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$122.50 High Stock Price Target$175.00 Low Stock Price Target$100.00 Potential Upside/Downside+43.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$6.01 Trailing P/E Ratio14.17 Forward P/E Ratio14.22 P/E GrowthN/ANet Income$326.66 million Net Margins28.57% Pretax Margin38.09% Return on Equity44.29% Return on Assets23.52% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio4.41 Sales & Book Value Annual Sales$1.30 billion Price / Sales4.57 Cash Flow$6.57 per share Price / Cash Flow12.97 Book Value$16.97 per share Price / Book5.02Miscellaneous Outstanding Shares69,530,000Free Float68,484,000Market Cap$5.92 billion OptionableOptionable Beta0.51 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:LNTH) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.